Journal
PHARMACEUTICS
Volume 15, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics15041314
Keywords
copper(II) complexes; quinolinonato derivatives; cytochrome P450; isothermal titration calorimetry
Categories
Ask authors/readers for more resources
Two anticancer copper(II) mixed-ligand complexes were found to significantly inhibit different isoenzymes of cytochrome P450 (CYP), which may conflict with the metabolic pathways of chemotherapeutic agents.
The effects of two anticancer active copper(II) mixed-ligand complexes of the type [Cu(qui)(mphen)]Y center dot H2O, where Hqui = 2-phenyl-3-hydroxy- 1H-quinolin-4-one, mphen = bathophenanthroline, and Y = NO3 (complex 1) or BF4 (complex 2) on the activities of different isoenzymes of cytochrome P450 (CYP) have been evaluated. The screening revealed significant inhibitory effects of the complexes on CYP3A4/5 (IC50 values were 2.46 and 4.88 mu M), CYP2C9 (IC50 values were 16.34 and 37.25 mu M), and CYP2C19 (IC50 values were 61.21 and 77.07 mu M). Further, the analysis of mechanisms of action uncovered a non-competitive type of inhibition for both the studied compounds. Consequent studies of pharmacokinetic properties proved good stability of both the complexes in phosphate buffer saline (>96% stability) and human plasma (>91% stability) after 2 h of incubation. Both compounds are moderately metabolised by human liver microsomes (<30% after 1 h of incubation), and over 90% of the complexes bind to plasma proteins. The obtained results showed the potential of complexes 1 and 2 to interact with major metabolic pathways of drugs and, as a consequence of this finding, their apparent incompatibility in combination therapy with most chemotherapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available